OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation...
-
Upload
gertrude-simmons -
Category
Documents
-
view
223 -
download
0
description
Transcript of OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation...
![Page 1: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/1.jpg)
OCTGT Guidance Document Update
Rachael Anatol, Ph.D.Associate Director for Policy-New
LegislationFebruary 26, 2014
![Page 2: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/2.jpg)
Outline• Good Guidance Practices• Guidance basics• Guidances issued by OCTGT since 2009• OCTGT 2014 Guidance Agenda
![Page 3: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/3.jpg)
Good Guidance Practices (GGPs)• FDA’s policies and procedures for
developing, issuing, and using guidance documents
• Require FDA to publish yearly guidance agenda
• Call for public participation
![Page 4: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/4.jpg)
Guidance Document Basics• Documents prepared for FDA,
applicants/sponsors, and the public that describe FDA’s interpretation of or policy on a regulatory issue
• First means of communication to a broad audience
• Not legally binding
![Page 5: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/5.jpg)
Guidance Document Topics• Design, production, labeling, promotion,
manufacturing, and testing of regulated products
• Processing, content, and evaluation or approval of submissions
• Inspection and enforcement policies
![Page 6: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/6.jpg)
OCTGT Draft Guidance Documents Published Since Last Update
• Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) ; 2013
• Draft Guidance for Industry: Use of Donor Screening Tests to Test Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for Infection with Treponema pallidum (Syphilis) ; 2013
• Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; 2013
• Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System; 2013
• Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System; 2013
![Page 7: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/7.jpg)
OCTGT Final Guidance Documents Published Since Last Update
• Preclinical Assessment of Investigational Cellular and Gene Therapy Products; 2013
• Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage; 2011
• Clinical Considerations for Therapeutic Cancer Vaccines; 2011• Potency Tests for Cellular and Gene Therapy Products; 2011• Current Good Tissue Practice (CGTP) and Additional
Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); 2011
• Class II Special Controls Guidance Document: Cord Blood Processing System and Storage Container; 2011
• Cellular Therapy for Cardiac Disease; 2010• Considerations for Allogeneic Pancreatic Islet Cell Products;
2009
![Page 8: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/8.jpg)
OCTGT Guidances on 2014 CBER Guidance Agenda
• Draft Guidance for Industry: Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products
• Draft Guidance for Industry: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue Based Products
• Final Guidance for Industry: Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System
• Final Guidance for Industry: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System
![Page 9: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/9.jpg)
OCTGT Contact Information• Rachael Anatol: [email protected] • Regulatory Questions:
Contact the Regulatory Management Staff in OCTGT at [email protected] or [email protected] or by calling (301) 827-6536
• OCTGT Learn Webinar Series: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ucm232821.htm
9
![Page 10: OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February…](https://reader036.fdocuments.in/reader036/viewer/2022070616/5a4d1beb7f8b9ab0599e4111/html5/thumbnails/10.jpg)
Public Access to CBERCBER website:http://www.fda.gov/BiologicsBloodVaccines/default.htm.
Cellular and gene therapy guidances:http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/
default.htm
Tissue guidances:http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/default.htm
All biologics guidance and CBER 2014 guidance agenda:http://www.fda.gov/biologicsbloodVaccines/GuidanceComplianceRegulatoryInformation/guidances/default.htm
Consumer Affairs Branch (CAB) Email: [email protected]
Phone: 301-827-3821
Manufacturers Assistance & Technical Training Branch (MATTB)Email: [email protected]
Phone: 301-827-4081
Follow us on Twitter https://www.twitter.com/fdacber